Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | ATP4A | P20648 | 1/20 | 0.44 |
| ▸ | ATP4B | P51164 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | MGMT | P16455 | 4/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | EPX | P11678 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402887 | 0.87 | L3MBTL1 (0.48) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL311056 | 0.82 | MGMT (0.59) | L3MBTL1LTA4HMAPK14MGMTLMNA | |
| SCHEMBL1232862 | 0.81 | L3MBTL1 (0.57) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL4376577 | 0.76 | EGFR (0.42) | CYP3A4MPOHRH4CYP1A2CYP2D6 | |
| SCHEMBL2400247 | 0.75 | L3MBTL1 (0.47) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL312251 | 0.75 | CYP3A4 (0.49) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL2400897 | 0.75 | L3MBTL1 (0.53) | L3MBTL1CYP3A4PDE5AMGMTMPO | |
| SCHEMBL13313402 | 0.74 | L3MBTL1 (0.49) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL16852229 | 0.74 | MGMT (0.64) | L3MBTL1LTA4HMAPK14CYP3A4PDE5A | |
| SCHEMBL1936855 | 0.73 | LTA4H (0.59) | L3MBTL1LTA4HMAPK14CYP3A4ATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1831221-B1 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMANY | 2011-12-01 | — | — | US | disclosed |
| US-8034938-B2 | Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1831221-A4 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1831226-A4 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2008-04-10 | — | — | US | disclosed |
| EP-1831221-A2 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M Innovative Properties Company (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831226-A2 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006083440-A2 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | L3MBTL1 2937/4885LTA4H 1719/4885MAPK14 3941/4885 |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | L3MBTL1 2904/4885LTA4H 1708/4885MAPK14 3968/4885 |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IFNAR1 | L3MBTL1 2802/4885LTA4H 1972/4885MAPK14 1870/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | L3MBTL1 2937/4885LTA4H 1719/4885MAPK14 3941/4885 |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNG, IL4, IFNAR1 | L3MBTL1 2802/4885LTA4H 1972/4885MAPK14 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.